ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S….
Uncategorized
Federal budget proposal funds NEI, vision injury research
A 2026 budget proposal that retains the National Eye Institute as a stand-alone entity at NIH is advancing through Congress ahead of a Jan. 30 government funding deadline.The proposed HHS budget also revives a vision injury research program defunded la…
Uncategorized
FDA clears investigational new drug application for NOV05
The FDA cleared an investigational new drug application to advance NOV05 in a phase 2 clinical trial in noninfectious anterior uveitis, according to a press release from Novaliq.The randomized, double-masked EYETAC clinical trial will evaluate NOV05 (t…
Uncategorized
Drug Farm Announces FDA Fast Track Designation for First-in-Class ALPK1 Inhibitor DF-003 for the Treatment of ROSAH Syndrome
ALBANY, N.Y. & SHANGHAI–(BUSINESS WIRE)–FDA fast tracks DF-003 for ROSAH syndrome, announces Drug Farm.
Uncategorized
Personalized Ophthalmology Therapies Market Report 2025: $5.46 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2019-2024, 2024-2029F, 2034F – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Personalized Ophthalmology Therapies Market Report 2025” has been added to ResearchAndMarkets.com’s offering. The personalized ophthalmology therapies market is experiencing significant growth, with an expected increase fr…
Uncategorized
Sunshine Eye & Retina to feature actionable insights
Sunshine Eye & Retina, formerly known as Telling It Like It Is, will be held from March 26 to 29 at the Fontainebleau Miami Beach.Hosted by Healio LIVE, the meeting will feature new events such as the Corneal Health Roundtable, the Retina Case Conferen…